Comparison · Tirzepatide

Compounded tirzepatide versus Zepbound

Zepbound is an FDA-approved medicine. Compounded tirzepatide is not. That is the whole comparison, and no price difference changes it — but the price difference is real and large enough that people reasonably want the arithmetic laid out.

The two numbers

The lowest FDA-approved brand channel in this database is LillyDirect (Zepbound) at $449 a month, or $5,388 across a year at that rate. The cheapest compounded tirzepatide program is NexLife at $169 a month all-in, or $1,668 across a year. The difference is roughly $280 a month.

Both figures include everything mandatory. Neither includes anything optional.

What the price difference actually buys

The approved product has been through FDA review for safety, effectiveness and manufacturing quality. Its labelling is the result of that review. Its manufacturing is inspected against approved-drug standards. When you take it, the identity, potency and sterility of what is in the vial are backed by that whole apparatus.

A compounded product has not been through any of that. The FDA does not review compounded drugs before they are dispensed. Compounded tirzepatide is not a generic of Zepbound — a generic is an approved product demonstrated equivalent to the original, and no such thing exists here. The price gap is a regulatory gap as much as a manufacturing one.

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Shortage-era discretion that had permitted large-scale compounding of copies wound down through early 2025. What remains is 503A compounding against documented patient-specific clinical need, in a contested legal environment where the boundaries are still being litigated and the rules have continued to move.

Practically, that means a compounded program's availability is less certain than an approved product's, and it means the honest framing of the price difference includes the possibility that a given compounded lane closes.

How people actually decide

Cost is the obvious axis and usually the deciding one. But two others matter and get less attention. Insurance coverage can move the approved product below its cash price entirely, which makes the cash-price comparison above irrelevant for anyone with coverage — check that first. And continuity matters: switching between a compounded product and an approved one mid-titration is a conversation to have with a clinician, not a price optimisation.

If you do go the compounded route, the pharmacy verification guide is the thing to read next, because in the absence of FDA pre-market review the pharmacy's identity and inspection history is most of what you have.

Questions

Is compounded tirzepatide the same as Zepbound?

No. Zepbound is FDA-approved; compounded tirzepatide is not, and it is not a generic. The FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed.

How much cheaper is compounded tirzepatide?

In this database the cheapest compounded program is NexLife at $169 a month all-in, against LillyDirect (Zepbound) at $449 — a difference of about $280 a month at cash prices. Insurance coverage can change that comparison entirely.

Is compounded tirzepatide legal?

503A compounding against documented patient-specific clinical need continues, in a contested legal environment. The shortage-era discretion that permitted large-scale compounding of copies ended through early 2025 after the FDA resolved the tirzepatide and semaglutide shortages.